Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review
Authors:
- Samuel J. Martínez-DomínguezSMSamuel J. Martínez-Domínguez
- Sandra García-MateoSGSandra García-Mateo
- Viviana LaredoVLViviana Laredo
- Carla J. Gargallo-PuyueloCGCarla J. Gargallo-Puyuelo
- Beatriz Gallego LleraBLBeatriz Gallego Llera
- Julia López de la CruzJCJulia López de la Cruz
- Fernando GomollónFGFernando Gomollón
Open Access
Abstract
The aim of the systematic review is to assess the prevalence and risk factors of liver fibrosis in patients with Inflammatory Bowel Disease (IBD) and Non-Alcoholic Fatty Liver Disease (NAFLD) and to discuss the role of liver fibrosis in the progression to hepatocellular carcinoma (HCC). We performed a structured search in PubMed, Web of Science, Embase, and Scopus up to 3 March 2023 to identify observational studies reporting liver fibrosis in patients with NAFLD and IBD. Quality of studies was assessed using the Newcastle-Ottawa Scale (NOS) score. A total of 23 studies met our inclusion criteria, including 629,781 patients. A total of 10 cross-sectional, 3 case-control, and 10 cohort studies were included. Fourteen studies had a NOS score ≥ 7 points. NAFLD was diagnosed in 2162/6332 (34.1%) IBD participants. However, NAFLD diagnosis was established in 924/2962 (31.2%) healthy individuals without IBD. Advanced liver fibrosis was found in 116 (11.6%) of 992 IBD patients with NAFLD. Most studies found an association between NAFLD and classic cardiovascular risk factors such as older age, male sex, higher BMI, diabetes, hypertension and dyslipidemia. In addition, metabolic syndrome features were also associated with an increased risk of significant and advanced liver fibrosis. Although no strong association between NAFLD and IBD therapy was reported, some studies associated NAFLD with IBD diagnosis, Crohn’s Disease, a complicated course of IBD, disease activity, and IBD duration. Advanced liver fibrosis was also associated with Crohn’s disease in several studies. In conclusion, NAFLD and advanced liver fibrosis are prevalent and clinically relevant extraintestinal manifestations, so its diagnosis and potential progression to HCC should be carefully considered in daily clinical practice.Keywords
This publication has 82 references indexed in Scilit:
- Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinomaJournal of Hepatology, 2014
- Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)Digestive Diseases and Sciences, 2013
- Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis predictionMolecular Carcinogenesis, 2013
- Are healthcare workers’ intentions to vaccinate related to their knowledge, beliefs and attitudes? a systematic reviewBMC Public Health, 2013
- PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individualsDigestive and Liver Disease, 2012
- Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver diseaseHepatology, 2011
- The Association of Genetic Variability in Patatin-Like Phospholipase Domain-Containing Protein 3 (PNPLA3) with Histological Severity of Nonalcoholic Fatty Liver Disease†Hepatology, 2010
- Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease†Hepatology, 2010
- Independent Predictors of Fibrosis in Patients With Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2009
- Recurrent Obscure Gastrointestinal Bleeding in a Patient With Gastric AmyloidClinical Gastroenterology and Hepatology, 2009